Document Detail


Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men.
MedLine Citation:
PMID:  23148280     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The worldwide epidemic of obesity is a major public health concern and is persuasively linked to the rising prevalence of diabetes and cardiovascular disease. Obesity is often associated with an abnormal lipoprotein profile, which may be partly negated by pioglitazone intervention, as this can influence the composition and oxidation characteristics of low-density lipoprotein (LDL). However, as pioglitazone's impact on these parameters within high-density lipoprotein (HDL), specifically HDL(2&3), is absent from the literature, this study was performed to address this shortcoming.
METHODS: Twenty men were randomized to placebo or pioglitazone (30 mg/day) for 12 weeks. HDL(2&3) were isolated by rapid-ultracentrifugation. HDL(2&3)-cholesterol and phospholipid content were assessed by enzymatic assays and apolipoprotein AI (apoAI) content by single-radial immunodiffusion. HDL(2&3) oxidation characteristics were assessed by monitoring conjugated diene production and paraoxonase-1 activity by spectrophotometric assays.
RESULTS: Compared with the placebo group, pioglitazone influenced the composition and oxidation potential of HDL(2&3). Specifically, total cholesterol (P < 0.05), phospholipid (P < 0.001) and apoAI (P < 0.001) were enriched within HDL(2). Furthermore, the resistance of HDL(2&3) to oxidation (P < 0.05) and the activity of paroxonase-1 were also increased (P < 0.001).
CONCLUSIONS: Overall, these findings indicate that pioglitazone treatment induced antiatherogenic changes within HDL(2&3), which may help reduce the incidence of premature cardiovascular disease linked with obesity.
Authors:
Jane McEneny; Peter A McPherson; Ann McGinty; Stephen S Hull; David R McCance; Ian S Young
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2012-11-12
Journal Detail:
Title:  Annals of clinical biochemistry     Volume:  50     ISSN:  1758-1001     ISO Abbreviation:  Ann. Clin. Biochem.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-02-18     Completed Date:  2013-07-30     Revised Date:  2013-10-21    
Medline Journal Info:
Nlm Unique ID:  0324055     Medline TA:  Ann Clin Biochem     Country:  England    
Other Details:
Languages:  eng     Pagination:  20-4     Citation Subset:  IM    
Affiliation:
Centre for Public Health, Queen's University Belfast, Nutrition & Metabolism Group, Grosvenor Road, Belfast BT12 6BJ, UK. j.mceneny@qub.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Apolipoprotein A-I / blood*
Aryldialkylphosphatase / blood*
Body Mass Index
Cardiovascular Diseases / blood,  etiology,  prevention & control
Cholesterol, HDL / blood*
Fasting
Humans
Hypoglycemic Agents / pharmacology*
Immunodiffusion
Male
Middle Aged
Obesity / blood*,  complications
Oxidation-Reduction
Spectrophotometry
Thiazolidinediones / pharmacology*
Ultracentrifugation
Chemical
Reg. No./Substance:
0/Apolipoprotein A-I; 0/Cholesterol, HDL; 0/Hypoglycemic Agents; 0/Thiazolidinediones; EC 3.1.8.1/Aryldialkylphosphatase; X4OV71U42S/pioglitazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vitamin A supplementation, serum lipids, liver enzymes and C-reactive protein concentrations in obes...
Next Document:  Impact of prandial status on the comparison of capillary glucose meter and venous plasma glucose mea...